Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Revenue, Net (Deprecated 2018-01-31)

2.8 / 5 stars · 68/120 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Revenue, Net (Deprecated 2018-01-31)

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Revenue, Net (Deprecated 2018-01-31) of $5.69 billion for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.

Discontinued › Income Statement

us-gaap:SalesRevenueNet · last filed 2018-10-25

  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for the quarter ending 2018-09-30 was $5.69B, a 8.32% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $5.70B, a 10.89% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $5.19B, a 5.36% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.45B, a 3.93% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for fiscal 2017 was $20.78B, a 6.94% increase from fiscal 2016.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for fiscal 2016 was $19.43B, a 17.31% increase from fiscal 2015.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for fiscal 2015 was $16.56B, a 4.29% increase from fiscal 2014.
  • BRISTOL-MYERS SQUIBB COMPANY revenue, net (deprecated 2018-01-31) for fiscal 2014 was $15.88B, a 3.09% decline from fiscal 2013.
Period endRevenue, Net (Deprecated 2018-01-31) 3 monthRevenue, Net (Deprecated 2018-01-31) 3 month as first filedRevenue, Net (Deprecated 2018-01-31) 6 monthRevenue, Net (Deprecated 2018-01-31) 6 month as first filedRevenue, Net (Deprecated 2018-01-31) 9 monthRevenue, Net (Deprecated 2018-01-31) 9 month as first filedRevenue, Net (Deprecated 2018-01-31) 12 month
2018-09-30$5.69B
10-Q · filed 2018-10-25
$11.39B
derived: sum of 2 quarters · filed 2018-10-25
$16.59B
10-Q · filed 2018-10-25
$22.04B
derived: sum of 4 quarters · filed 2018-10-25
2018-06-30$5.70B
10-Q · filed 2018-07-26
$10.90B
10-Q · filed 2018-07-26
$16.35B
derived: sum of 3 quarters · filed 2018-07-26
$21.60B
derived: sum of 4 quarters · filed 2018-10-25
2018-03-31$5.19B
10-Q · filed 2018-04-26
$10.64B
derived: sum of 2 quarters · filed 2018-04-26
$15.90B
derived: sum of 3 quarters · filed 2018-10-25
$21.04B
derived: sum of 4 quarters · filed 2018-10-25
2017-12-31$5.45B
10-K · filed 2018-02-13
$10.70B
derived: sum of 2 quarters · filed 2018-10-25
$15.85B
derived: sum of 3 quarters · filed 2018-10-25
$20.78B
10-K · filed 2018-02-13
2017-09-30$5.25B
10-Q · filed 2018-10-25
$10.40B
derived: sum of 2 quarters · filed 2018-10-25
$15.33B
10-Q · filed 2018-10-25
$20.57B
derived: sum of 4 quarters · filed 2018-10-25
2017-06-30$5.14B
10-Q · filed 2018-07-26
$10.07B
10-Q · filed 2018-07-26
$15.32B
derived: sum of 3 quarters · filed 2018-07-26
$20.24B
derived: sum of 4 quarters · filed 2018-07-26
2017-03-31$4.93B
10-Q · filed 2018-04-26
$10.17B
derived: sum of 2 quarters · filed 2018-04-26
$15.09B
derived: sum of 3 quarters · filed 2018-04-26
$19.96B
derived: sum of 4 quarters · filed 2018-04-26
2016-12-31$5.24B
10-K · filed 2018-02-13
$10.16B
derived: sum of 2 quarters · filed 2018-02-13
$15.04B
derived: sum of 3 quarters · filed 2018-02-13
$19.43B
10-K · filed 2018-02-13
2016-09-30$4.92B
10-K · filed 2018-02-13
$9.79B
derived: sum of 2 quarters · filed 2018-02-13
$14.18B
10-Q · filed 2017-10-26
$18.47B
derived: sum of 4 quarters · filed 2018-02-13
2016-06-30$4.87B
10-K · filed 2018-02-13
$9.26B
10-Q · filed 2017-07-27
$13.55B
derived: sum of 3 quarters · filed 2018-02-13
$17.62B
derived: sum of 4 quarters · filed 2018-02-13
2016-03-31$4.39B
10-K · filed 2018-02-13
$8.68B
derived: sum of 2 quarters · filed 2018-02-13
$12.75B
derived: sum of 3 quarters · filed 2018-02-13
$16.91B
derived: sum of 4 quarters · filed 2018-02-13
2015-12-31$4.29B
10-K · filed 2017-02-21
$8.36B
derived: sum of 2 quarters · filed 2017-02-21
$12.52B
derived: sum of 3 quarters · filed 2017-02-21
$16.56B
10-K · filed 2018-02-13
2015-09-30$4.07B
10-K · filed 2017-02-21
$8.23B
derived: sum of 2 quarters · filed 2017-02-21
$12.27B
10-Q · filed 2016-10-27
$16.53B
derived: sum of 4 quarters · filed 2017-02-21
2015-06-30$4.16B
10-K · filed 2017-02-21
$8.20B
10-Q · filed 2016-07-28
$12.46B
derived: sum of 3 quarters · filed 2017-02-21
$16.38B
derived: sum of 4 quarters · filed 2017-02-21
2015-03-31$4.04B
10-K · filed 2017-02-21
$8.30B
derived: sum of 2 quarters · filed 2017-02-21
$12.22B
derived: sum of 3 quarters · filed 2017-02-21
$16.11B
derived: sum of 4 quarters · filed 2017-02-21
2014-12-31$4.26B
10-K · filed 2016-02-12
$8.18B
derived: sum of 2 quarters · filed 2016-02-12
$12.07B
derived: sum of 3 quarters · filed 2016-02-12
$15.88B
10-K · filed 2017-02-21
2014-09-30$3.92B
10-K · filed 2016-02-12
$7.81B
derived: sum of 2 quarters · filed 2016-02-12
$11.62B
10-Q · filed 2015-10-27
$16.06B
derived: sum of 4 quarters · filed 2016-02-12
2014-06-30$3.89B
10-K · filed 2016-02-12
$7.70B
10-Q · filed 2015-07-23
$12.14B
derived: sum of 3 quarters · filed 2016-02-12
$16.21B
derived: sum of 4 quarters · filed 2016-02-12
2014-03-31$3.81B
10-K · filed 2016-02-12
$8.25B
derived: sum of 2 quarters · filed 2016-02-12
$12.32B
derived: sum of 3 quarters · filed 2016-02-12
$16.36B
derived: sum of 4 quarters · filed 2016-02-12
2013-12-31$4.44B
10-K · filed 2015-02-13
$8.51B
derived: sum of 2 quarters · filed 2015-02-13
$12.55B
derived: sum of 3 quarters · filed 2015-02-13
$16.39B
10-K · filed 2016-02-12
2013-09-30$4.07B
10-K · filed 2015-02-13
$8.11B
derived: sum of 2 quarters · filed 2015-02-13
$11.94B
10-Q · filed 2014-10-24
$16.14B
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30$4.05B
10-K · filed 2015-02-13
$7.88B
10-Q · filed 2014-07-24
$12.07B
derived: sum of 3 quarters · filed 2015-02-13
$15.81B
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31$3.83B
10-K · filed 2015-02-13
$8.02B
derived: sum of 2 quarters · filed 2015-02-13
$11.76B
derived: sum of 3 quarters · filed 2015-02-13
$16.20B
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31$4.19B
10-K · filed 2014-02-14
$7.93B
derived: sum of 2 quarters · filed 2014-02-14
$12.37B
derived: sum of 3 quarters · filed 2014-02-14
$17.62B
10-K · filed 2015-02-13
2012-09-30$3.74B
10-K · filed 2014-02-14
$8.18B
derived: sum of 2 quarters · filed 2014-02-14
$13.43B
10-Q · filed 2013-10-23
$18.88B
derived: sum of 4 quarters · filed 2014-02-14
2012-06-30$4.44B
10-K · filed 2014-02-14
$9.69B
10-Q · filed 2013-07-25
$15.15B
derived: sum of 3 quarters · filed 2014-02-14
$20.49B
derived: sum of 4 quarters · filed 2014-02-14
2012-03-31$5.25B
10-K · filed 2014-02-14
$10.71B
derived: sum of 2 quarters · filed 2014-02-14
$16.05B
derived: sum of 3 quarters · filed 2014-02-14
$21.48B
derived: sum of 4 quarters · filed 2014-02-14
2011-12-31$5.45B
10-K · filed 2013-02-15
$10.80B
derived: sum of 2 quarters · filed 2013-02-15
$16.23B
derived: sum of 3 quarters · filed 2013-02-15
$21.24B
10-K · filed 2014-02-14
2011-09-30$5.34B
10-K · filed 2013-02-15
$10.78B
derived: sum of 2 quarters · filed 2013-02-15
$15.79B
10-Q · filed 2012-10-24
$20.90B
derived: sum of 4 quarters · filed 2013-02-15
2011-06-30$5.43B
10-K · filed 2013-02-15
$10.45B
10-Q · filed 2012-07-25
$15.56B
derived: sum of 3 quarters · filed 2013-02-15
$20.35B
derived: sum of 4 quarters · filed 2013-02-15
2011-03-31$5.01B
10-K · filed 2013-02-15
$10.12B
derived: sum of 2 quarters · filed 2013-02-15
$14.92B
derived: sum of 3 quarters · filed 2013-02-15
$19.69B
derived: sum of 4 quarters · filed 2013-02-15
2010-12-31$5.11B
10-K · filed 2012-02-17
$9.91B
derived: sum of 2 quarters · filed 2012-02-17
$14.68B
derived: sum of 3 quarters · filed 2012-02-17
$19.48B
10-K · filed 2013-02-15
2010-09-30$4.80B
10-K · filed 2012-02-17
$9.57B
derived: sum of 2 quarters · filed 2012-02-17
$14.37B
10-Q · filed 2011-10-27
$19.41B
derived: sum of 4 quarters · filed 2012-02-17
2010-06-30$4.77B
10-K · filed 2012-02-17
$9.57B
10-Q · filed 2011-07-28
$14.61B
derived: sum of 3 quarters · filed 2012-02-17
$19.40B
derived: sum of 4 quarters · filed 2012-02-17
2010-03-31$4.81B
10-K · filed 2012-02-17
$9.84B
derived: sum of 2 quarters · filed 2012-02-17
$14.63B
derived: sum of 3 quarters · filed 2012-02-17
$19.29B
derived: sum of 4 quarters · filed 2012-02-17
2009-12-31$5.03B
10-K · filed 2011-02-18
$9.82B
derived: sum of 2 quarters · filed 2011-02-18
$14.49B
derived: sum of 3 quarters · filed 2011-02-18
$18.81B
10-K · filed 2012-02-17
2009-09-30$4.79B
10-K · filed 2011-02-18
$5.49B
10-Q · filed 2009-10-22
$9.45B
derived: sum of 2 quarters · filed 2011-02-18
$13.78B
10-Q · filed 2010-10-26
$15.89B
10-Q · filed 2009-10-22
$16.14B
derived: sum of 4 quarters · filed 2011-02-18
2009-06-30$4.67B
10-K · filed 2011-02-18
$5.38B
10-Q · filed 2009-07-23
$8.99B
10-Q · filed 2010-07-22
$10.40B
10-Q · filed 2009-07-23
$11.35B
derived: sum of 3 quarters · filed 2011-02-18
$16.61B
derived: sum of 4 quarters · filed 2011-02-18
2009-03-31$4.32B
10-K · filed 2011-02-18
$6.69B
derived: sum of 2 quarters · filed 2011-02-18
$11.94B
derived: sum of 3 quarters · filed 2011-02-18
$17.15B
derived: sum of 4 quarters · filed 2011-02-18
2008-12-31$2.37B
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18
$7.62B
derived: sum of 2 quarters · filed 2011-02-18
$12.82B
derived: sum of 3 quarters · filed 2011-02-18
$17.71B
10-K · filed 2011-02-18
2008-09-30$5.25B
10-Q · filed 2009-10-22
$10.46B
derived: sum of 2 quarters · filed 2009-10-22
$15.35B
10-Q · filed 2009-10-22
2008-06-30$5.20B
10-Q · filed 2009-07-23
$10.09B
10-Q · filed 2009-07-23
2007-12-31$15.62B
10-K · filed 2010-02-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64